| Factor Information | |
|---|---|
| Data ID | 3342 |
| Factor | vascular endothelial growth factor expression |
| Description | PHT=pulmonary hypertension; eNOS=endothelial nitric oxide synthase |
| Biomarker | YES |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | risk assessment |
| Objective | This study sought to assess the cellular and histologic basis of irreversible pulmonary hypertension (PHT) in the clinical setting of congenital heart disease (CHD). |
| p Value | <0.001 |
| Conclusion | Irreversible PHT is strongly associated with impaired endothelial cell apoptosis and antiapoptotic signaling from perivascular inflammatory cells. These changes are associated with intimal proliferation and vessel narrowing, and thereby may contribute to clinical outcomes associated with pulmonary hypertension. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 17306711 |
| Year | 2007 |
| Title | Impaired Apoptosis of Pulmonary Endothelial Cells Is Associated With Intimal Proliferation and Irreversibility of Pulmonary Hypertension in Congenital Heart Disease |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | patients' data | |
| Region | Sydney, Australia | |
| Method | Mann-Whitney U test | |
| Race | Austrian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | irreversible PHT(Treatment) | reversible PHT(Control) |
| Number | N/A | N/A |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 2.9±0.5 | 0.5±0.1 |
